Sign in
Taking people in United StatesPhase 2

Fluciclovine PET scan to check for leftover tumor after brain metastasis surgery

Tests 18F-Fluciclovine PET imaging in people after surgery for brain metastases.

Key facts

Who runs it
Baptist Health South Florida
Where
Miami, United StatesSee the site
Trial code
Registry title
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
10 Jan 2023
Expected to end
Jan 2030
Type of study
Interventional
Treatments tested
  • 18F-Fluciclovine
Record updated
1 December 2025

Who can take part

The trial is looking for adults with cancer that has spread to the brain (brain metastasis). They must be planned for surgery and then focused radiation (SRS) after surgery.

Age
18 years or older
Sex
All sexes
Disease stage
Brain metastasis seen on scans. Surgery is planned for at least 1 metastasis, then SRS after surgery. Daily activity level ECOG 0-3.
Earlier treatment
People who have had whole-brain radiation therapy before cannot join.
Main reasons for not taking part
  • Severe allergic reaction (anaphylaxis) to 18F-Fluciclovine in the past
  • Signs of cancer in the lining of the brain and spinal cord (leptomeningeal disease)
  • Cannot have an MRI, for example because of a pacemaker
  • Pregnant at the time of the 18F-fluciclovine scan
  • Breastfeeding and not willing to stop for 24 hours after the scan
Show the full registry criteria (27)Hide the full registry criteria

Who can take part

  • Age ≥ 18 years
  • Performance status, Eastern Cooperative Oncology Group (ECOG) 0-3
  • Radiographic diagnosis of brain metastasis
  • Patient planned for surgical intervention for at least 1 metastasis
  • Patient planned for postoperative SRS; Male or female patients of reproductive potential need to employ two highly effective and acceptable forms of contraception for at least 4 weeks prior to screening and agreement to use such a method during study participation and for an additional 1 week after post-treatment 18F-Fluciclovine PET/CT. Highly effective and acceptable forms of contraception are:
  • Male condom plus spermicide
  • Cap plus spermicide
  • Diaphragm plus spermicide
  • Copper T
  • Progesterone T
  • Levonorgestrel-releasing intrauterine system (e.g., Mirena®)
  • Implants
  • Hormone shot or injection
  • Combined pill
  • Mini-pill
  • Patch; Postmenopausal people on the study (that will not need contraception) is defined as at least one of the following:
  • Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments
  • Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the postmenopausal range for women under 50
  • Radiation-induced oophorectomy with last menses > 1 year ago
  • Chemotherapy-induced menopause with >1 year interval since last menses
  • Surgical sterilization (bilateral oophorectomy or hysterectomy)

Who cannot take part

  • Prior anaphylactic reaction to 18F-Fluciclovine
  • Prior whole-brain radiation therapy
  • Evidence of leptomeningeal disease
  • Contraindication to MRI (e.g., due to safety reasons, such as presence of a pacemaker)
  • Pregnant at the expected time of 18F-fluciclovine administration
  • Expecting to be breastfeeding at the time of 18F-Fluciclovine and unwilling to stop breast-feeding for 24 hours. Temporary cessation of breastfeeding 24 hours after the time of imaging is allowed

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Brain metastases or brain cancer

This trial is currently available in United States.

  • Miami Cancer Institute at Baptist Health South FloridaMiami, United StatesContact: Rupesh Kotecha, MDTaking people

About the trial

What the trial wants to find out

This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific imaging agent, known as 18F-Fluciclovine, will help physicians evaluate the extent of surgery and determine if there is any visible tumor above what MRI alone can identify as well as improve the physicians' ability to detect recurring disease. This agent (18F-Fluciclovine) is investigational for the imaging of brain metastases.

The group in the trial

  • PET/CT, MRITreatment being tested

    All patients will obtain an 18F-Fluciclovine PET/CT scan in addition to the planning MRI at the time of SRS treatment (approximately 2-4 weeks after resection). The value of 18F-Fluciclovine in addition to structural information from the MRI will be analyzed. Patients will continue to undergo 18F-Fluciclovine in addition to MRI during routine follow-up to determine the ability of 18F-Fluciclovine PET/CT to identify areas at risk for marginal failure, monitor resection beds for tumor control, identify patients at risk for disease recurrence, and detect patterns of failure.

    Treatment: 18F-Fluciclovine

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
Plain-language title
Fluciclovine PET scan to check for leftover tumor after brain metastasis surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT05554302, who can take part
Record updated
1 December 2025